Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Natera (NTRA)

NASDAQ: NTRA · Diagnostics & Research · Austin, TX

Our rating: Neutral

Neutral reaffirmed at $288.48, moderate conviction, November 16, 2026.

Breaks if: On this Neutral call: we would turn Positive if revenue growth stays above 30% year-over-year and FCF margin breaks above 8% in the next two reported quarters — that would confirm operating leverage is arriving on schedule and that the valuation is being grown into. We would turn Cautious if revenue growth decelerates below 20% year-over-year or if free cash flow reverts to negative in either of the next two quarters, or if the November 13 patent invalidation expands to cover Natera's Signatera or Panorama platforms within the next twelve months.

Key figures

Market value$39.6B
Revenue, last 12 months$2.9B
Net income, last 12 months−$165M
Free cash flow, last 12 months$52M
Price to earningsn/a
Free cash flow yield0.1%
Dividend yield0.0%
Operating margin−9.0%
Return on equity−10.6%
Beta to the S&P 5001.34
Volatility, annualized48.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$794M34.1%$-0.42$5M
June 30, 2026$753M37.7%$-0.47−$9M
March 31, 2026$697M38.8%$-0.60$18M
December 31, 2025$665M39.8%$0.36$38M
September 30, 2025$592M34.7%$-0.64$37M
June 30, 2025$547M32.2%$-0.74$12M
March 31, 2025$502M36.5%$-0.50$23M
December 31, 2024$476M53.0%$-0.41$35M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

23 ledger entries and 13 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.